Navigation Links
The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Date:8/19/2007

Phase 2 Study to Explore the Efficacy of Novel Proteasome Inhibitor in

Patients with Relapsed and Refractory Multiple Myeloma

SOUTH SAN FRANCISCO, Calif. and NORWALK, Conn., Aug. 15 /PRNewswire/ -- The Multiple Myeloma Research Consortium (MMRC) and Proteolix, Inc. today announced the enrollment of the first patient in a multi-center Phase 2 clinical trial to study Proteolix's potent and selective proteasome inhibitor, carfilzomib (PR-171), in patients with relapsed and refractory multiple myeloma. Ten MMRC Member Institutions will participate in the study, under the MMRC leadership of Melissa Alsina, MD, H. Lee Moffitt Cancer Center & Research Institute. The nine additional sites are the City of Hope, Emory University, Cancer Center at Hackensack University Medical Center, Mayo Clinic, Princess Margaret/University Health Network, Saint Vincent's Comprehensive Cancer Center, University of Michigan, and Washington University.

The MMRC is the only research model of its kind that brings together 13 leading academic institutions to accelerate the development of novel and combination treatments for multiple myeloma, an incurable cancer of the plasma cell.

"Proteasome inhibitors are an important class of drugs for the treatment of multiple myeloma and we are proud to work with Proteolix to advance the clinical development of carfilzomib," said Kathy Giusti, Founder and Chief Executive Officer of the MMRC. "This trial and the others the MMRC are facilitating underscore our commitment to bring better, more effective treatments to myeloma patients as quickly as possible."

The trial will evaluate the overall response rate (ORR) for two cycles of carfilzomib in patients with multiple myeloma who have previously received specific FDA-approved therapies, have relapsed after two or more of such therapies, and are refractory to the most recently received therapy. Secondary objectives of this study include safety and tolerability, clinica
'/>"/>

SOURCE Proteolix

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Gentiums Defibrotide Seen as Active in Multiple Myeloma
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
7. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
10. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
11. Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... 1, 2015 CSSi, ( www.CSSiEnroll.com ) ... clinical research industry, recently partnered with a major ... that was falling quickly behind their enrollment timeline. ... site support programs, increased the number of patients ... increased the number of sites actively recruiting. Through ...
(Date:4/1/2015)... ANTONIO , April 1, 2015  The ... AirStrip® Sense4Baby™ wireless maternal/fetal ... the U.S. by pregnant patients to self-administer non-stress ... clearance from the FDA for use accompanied by ... from the European Commission in 2013 for self-administration, ...
(Date:4/1/2015)... -- MEI Pharma, Inc. (Nasdaq: MEIP ), an oncology ... cancer, announced today that Daniel P. Gold , Ph.D., ... th Annual Needham Healthcare Conference on Wednesday, April 15, ... Central Hotel in New York . A ... www.meipharma.com . A replay will be available approximately one hour ...
Breaking Medicine Technology:CSSi Quadruples Screening Activity and Speeds Enrollment for Pediatric Dermatology Study 2AirStrip Sense4Baby System Receives FDA Clearance for Patient Self-Administration 2AirStrip Sense4Baby System Receives FDA Clearance for Patient Self-Administration 3AirStrip Sense4Baby System Receives FDA Clearance for Patient Self-Administration 4MEI Pharma to Present at Needham Healthcare Conference 2
... 2011 Varian Medical Systems (NYSE: VAR ... to support the company,s ongoing growth and safety initiatives. ... for the company, has been named Chief Operating Officer ... promotion, and sale of all Varian products and services ...
... PARSIPPANY, N.J., Oct. 3, 2011 To help frustrated ... to their chronic nasal congestion and trouble with sleep, ... Sperling,s BestPlaces to identify the 20 Most Congested Cities ... top 20 metropolitan areas where residents are most challenged ...
Cached Medicine Technology:Varian Medical Systems Announces New Management Positions 2Varian Medical Systems Announces New Management Positions 3Varian Medical Systems Announces New Management Positions 420 Most Congested Cities in U.S. Unveiled 220 Most Congested Cities in U.S. Unveiled 320 Most Congested Cities in U.S. Unveiled 4
(Date:4/1/2015)... (PRWEB) April 01, 2015 The panel ... and telematics service providers to build a program that ... and complicated legal implications further down the line. This ... wake of the news that OBD-II port dongles aren’t ... In January, it was reported that Progressive’s Snapshot ...
(Date:4/1/2015)... 01, 2015 Taking an important step ... League for Nursing Commission for Nursing Education Accreditation (NLN ... the first NLN CNEA Board of Commissioners. Working with ... the 15-member board will provide leadership and direction to ... accreditation decisions for nursing programs that seek accreditation from ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 EAGAN, Minn. ... Minnesota and its family of companies (Blue Cross) today ... out the year with net income of $61.5 million, ... losses. The organization reported a net operating loss of ... a negative operating margin of one-tenth of one percent ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 GrassrootsHealth, ... announcing two continuing medical education (CME) courses about ... help practitioners become more confident in measuring, prescribing, ... After completion of these CME courses, practitioners can ... The CME courses available are “Vitamin D, Sunshine, ...
(Date:4/1/2015)... 01, 2015 Aging2.0 , the ... announces the launch of the Aging2.0 Alliance ... stakeholders and technology companies. The announcement was made today ... and Business Strategies Forum in San Diego, CA. ... Alliance program is now open for additional members. “This ...
Breaking Medicine News(10 mins):Health News:TU-Automotive: Office of The Privacy Commissioner of Canada To Set Out Privacy Considerations Surrounding UBI Products 2Health News:TU-Automotive: Office of The Privacy Commissioner of Canada To Set Out Privacy Considerations Surrounding UBI Products 3Health News:NLN Commission for Nursing Education Accreditation (NLN CNEA) Announces Inaugural Commissioners 2Health News:NLN Commission for Nursing Education Accreditation (NLN CNEA) Announces Inaugural Commissioners 3Health News:Blue Cross and Blue Shield of Minnesota Reports 2014 Results 2Health News:Blue Cross and Blue Shield of Minnesota Reports 2014 Results 3Health News:GrassrootsHealth Launches CME Courses about Vitamin D 2Health News:GrassrootsHealth Launches CME Courses about Vitamin D 3Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 2Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 3Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 4
... Free Wi-Fi System InstallationLANGHORNE, Pa., Jan. 26 Vector180 ... the region is the most "Worthy of Wi-Fi" and ... essay contest winner will receive a free site survey, ... best job of explaining how his or her facility ...
... Davos (SW) is - for the 18th time! - ... urological challenge and very enjoyable educational interactive forum. It ... Approximately 250 participants are expected to attend. , "Following ... once more use the format of a combination of ...
... Tripling the level of DHA (docosahexaenoic acid) in the ... improved the neurodevelopment outcome of girls, according to a study ... Journal of the American Medical Association (JAMA) . DHA is ... that is normally found in mother,s milk and, in recent ...
... LOUIS, Jan. 26 KV Pharmaceutical,(NYSE: KVa/KVb) has been ... (alpha hydroxyprogesterone caproate) will not be approved by,the U.S. ... met. , As previously disclosed, ... U.S. and worldwide rights to Gestiva upon approval of,the ...
... seem to increase risk, , , MONDAY, Jan. 26 (HealthDay News) ... calculate the risk a woman with cancer in one breast ... chances of developing cancer in a second breast, known as ... in one breast. And certain factors, such as a family ...
... moms, New Year Resolutions may,include "watch baby,s nutrition" this ... more than 400 American moms with infants or,toddlers across ... give,themselves a C or lower when it comes to ... and minerals. Hoping baby grows up strong and healthy, ...
Cached Medicine News:Health News:Non-Profit Healthcare Facilities Invited to Submit Essays in Vector180's 'Worthy Of Wi-Fi' Contest 2Health News:Interactive virtual training at European Urology Forum in Davos 2Health News:New Study: Higher DHA Levels Improve Neurodevelopmental Outcomes in Premature Girls 2Health News:New Study: Higher DHA Levels Improve Neurodevelopmental Outcomes in Premature Girls 3Health News:New Study: Higher DHA Levels Improve Neurodevelopmental Outcomes in Premature Girls 4Health News:New Survey: Moms Need More Help on Nutrition Information 2Health News:New Survey: Moms Need More Help on Nutrition Information 3Health News:New Survey: Moms Need More Help on Nutrition Information 4
... Revo Suture Anchor offers a simple and ... rotator cuff repair. The cutting tip requires ... with two #2 strands of braided polyester ... are avoided with the Independent Suture Sliding ...
The Atakr II RF Generator provides high power output with the integral safety of closed-loop temperature control using the embedded thermocouples in Medtronic RF ablation catheters....
... dedicated electrophysiology system on the market today, ... Fischer's patented "C inside a C" design ... the ultimate in patient access and flexibility. ... EPX2 minimizes equipment footprint and can be ...
... The requirements for Bi-Plane Electrophysiology imaging ... to decrease procedure time and reduce radiation ... become paramount in deciding between Single and ... goal of maintaining its leadership position in ...
Medicine Products: